Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2002

View Archived Issues

Vita launches Eneas in Spain

InKine and ZaBeCor form partnership to develop antisense and Fc receptor technologies

Vivus updates pipeline progress

Graffinity to identify hit compounds against Lilly targets

Essential Therapeutics' parenteral cephalosporin enters phase I

Marshall Edwards and NIDCR to study phenoxodiol

Sigma-Tau and Thuris enter research collaboration in age-related pathologies

Roche presents new mGluR5 antagonists for cognitive disorders, pain, etc.

Novel NHE3 inhibitors with potential in sleep apnea and other disorders

Abbott researchers discover series of histone deacetylase inhibitors

Novel p38-alpha kinase inhibitors in early development at Scios

Researchers at Signal identify compounds with JNK/IKK-2 inhibitory activity

Antitumor camptothecins designed by scientists at California Pacific Medical Center

Enrollment completed in two phase III trials for Axokine

CPMP hands down positive opinion for Cialis

Valcyte launched in U.K. for AIDS-related CMV retinitis

NicOx reviews first-half clinical developments

CPMP recommends approval of Somavert for acromegaly

Inhibitors of GSK-3 examined in vitro by Chiron in human skeletal muscle

Pharmos cleared to begin phase II trial of dexanabinol in heart surgery patients

Arius and Oxford BioMedica to develop cancer immunotherapeutics

Metabolites of DMXBA possess high efficacy at alpha7 receptors

Eisai to promote Pfizer's Cerebyx in U.S.

Japanese filing for Spiriva announced

Potent and selective TGF-beta type I receptor antagonist described in several recent publications

New erythromycin antibiotics identified at Ortho-McNeil